Wilex (Germany)

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

Ivar Bleumer, Alexander Knuth, Egbert Oosterwijk et al. · British Journal of Cancer · 2004 · 173 citations · Full text

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma

Karim Chamie, Nicholas M. Donin, Pia Klöpfer et al. · JAMA Oncology · 2016 · 134 citations · Full text

The urokinase plasminogen activator system as a novel target for tumour therapy

Manfred Schmitt, Olaf G. Wilhelm, Ute Reuning et al. · Fibrinolysis & proteolysis/Fibrinolysis and proteolysis · 2000 · 108 citations

Drug Targeting, Novel Therapy, Tumour Therapy +11

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

Michael Siebels, K. Rohrmann, R. Oberneder et al. · World Journal of Urology · 2010 · 101 citations

Urology, Genitourinary Cancer, Medicine +6

A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma

Ivar Bleumer, Egbert Oosterwijk, Jeannette Oosterwijk‐Wakka et al. · The Journal of Urology · 2005 · 91 citations